Equity Markets

Priced Before the Verdict

Moderna cleared every bar and lost $17 billion. An Iran contract sits in dispute at 98 cents. OpenAI's price reportedly slipped in talks and is still 47% above March.

Priced Before the Verdict
Priced Before the Verdict

Thursday handed investors plenty of evidence. The 10-year Treasury yield closed at 4.96%, its first close below 5% since September, while Brent settled at $113.17, its highest since May. The Nasdaq fell 2.6%. But prices weighed what the evidence left open. Good numbers got sold. Bonds and contracts picked sides before pending rulings, and private buyers kept bidding high.

Good Numbers Sold on What They Left Open

Each report cleared its bar. Each left the next question unanswered.

Moderna Cleared Every Published Bar and Lost $17 Billion

Moderna (MRNA) and Merck (MRK) released full Phase 3 melanoma vaccine data on Thursday, after a cancer conference said its embargo had been breached. Adding the vaccine to Keytruda cut the risk of recurrence or death by 42%. That cleared every published bar. Moderna still closed down 17.6%, about $17.2 billion of value. The catch was in the detail. A key secondary result trailed the smaller earlier trial, and for the first six months the two groups fared about the same.

Comfort Systems' Backlog Nearly Doubled. No Forecast Came With It.

Comfort Systems USA (FIX), a contractor whose work includes data centers, grew revenue 54%, and its backlog hit a record $17.81 billion, up 90% in a year. It gave no forward guidance and named a new finance chief. The stock fell anyway. Shares dropped 6.2% after hours, after an 8.7% slide during the session, before the report.

Newmont's Beat Was Priced at Last Quarter's Gold

Newmont (NEM) earned an adjusted $2.20 a share, above the $2.05 consensus, though production fell 8.5%. Price did the work. It sold gold at $4,317 an ounce, up 22%, and gold now trades more than 6% lower, headed for its steepest weekly drop in over four months. If prices hold, bigger fourth-quarter volumes will sell at a thinner margin.

Proof about the past. Doubt about the next.

Outlier Signal

All three beat the number they were judged on. Each left the next period open: whether the vaccine's late benefit holds, what the backlog will earn and what gold will pay.

The easy read is that the AI selloff dragged everything down. Yet biotech indexes fell less than 1% while Moderna fell 17.6%, which points to a market pricing Moderna's own data.

Saturday's full presentation at the congress is the first test. A rebound toward Wednesday's $245.81 close would say the market misread the data. Gold back above $4,317 would close Newmont's gap.

PREMIER FEATURE

The $16 Trillion Rare Earth Discovery

The Guardian calls it "the beginning of the biggest gold rush in history"... and one stock under $5 owns exclusive rights to harvest these rare earths.

Elon Musk and his companies need these minerals before a January 1 Pentagon deadline.

See the full story here.

Three Rulings Are Pending. The Prices Already Chose.

The facts are in. The prices have already picked a verdict.

France Shrank on the Day Moody's Rules

France's flash composite PMI fell to 48.4 in October from 51.1, and business confidence hit its lowest since 2012 outside the pandemic. The euro area as a whole kept growing. French 10-year yields closed Thursday near 5.13%, about 175 basis points over German debt, per central bank data. Then comes Moody's. It rates France Aa3 with a negative outlook and is due to rule after Europe's close on Friday.

A Disputed Iran Contract Still Trades Near 98 Cents

Polymarket's contract on the U.S.-Iran ceasefire holding through Oct. 22 hit its deadline on Thursday. By Friday morning it had not settled, and its status showed a dispute. The grounds are undisclosed. Only a U.S. strike on Iranian soil turns it to "no," and Central Command has not confirmed one. "Yes" still trades near 98 cents. The Oct. 24 contract rose to about 93 cents. Trump said the U.S. "may do it a little bit further," but the White House said it would not attack Iran before the midterms.

Brazil's Poll Is Tied. Its Contract Is Not.

A Datafolha poll released Thursday evening put Brazil's runoff at 50% to 50% in valid votes. Polymarket traders still give Flávio Bolsonaro about three-in-four odds. His contract dipped to 75.4 cents, then recovered to about 77, as traders appear to weight his first-round lead and two polls showing him ahead 52% to 48%. Still, Lula closed a two-point gap in a week. The vote is Sunday.

The rulings are pending. The bets are placed.

Outlier Signal

Each market reached a verdict early. French bonds sit at yields last seen in 2002 before Moody's has said a word, and the Iran contract prices the dispute to fail. Brazil's price favors the first round over the newest poll.

That makes the coming rulings lopsided. Being right pays 2 cents on a 98-cent contract and about 23 on Flávio, while being wrong costs the whole stake. Late buyers of the consensus are most exposed.

If French yields keep climbing on Monday after a one-notch cut from Moody's, due after Europe's close on Friday, the spread had not priced it. Sunday's count settles Brazil. The disputed Iran contract has no set date.

FROM OUR PARTNERS

You’re Being LIED To About The Iran War

Forget EVERYTHING you’ve heard about the Iran war.

Especially the reasons why we’re bombing the country.

Because THIS is the real reason.

Locked Money Is Still Bidding. Daily Money Left.

Funds that can sell every day sold. Funds that must invest are still investing.

OpenAI's Price Reportedly Slipped in Talks. It's Still 47% Above March.

OpenAI is close to raising up to $30 billion at $1.25 trillion before the new money, CNBC reported, with Coatue and investors from the United Arab Emirates leading. Bloomberg said the figure under discussion had been $1.4 trillion. That is 11% lower. It is still about 47% above March's round. Commitments are expected by the end of next week, one person said. Neither OpenAI nor its investors have said why the figure fell.

Private Lenders Have Record Money and Fewer Loans

Direct lenders had their worst quarter for new deals in more than three years, Bloomberg reported. Some of the largest are now chasing companies with under $20 million of annual earnings. The money keeps coming. Direct-lending funds raised a record $129.15 billion in nine months, per Preqin data, while about one in six private credit funds report non-accruals above 5%. Smaller borrowers tend to be more fragile.

Bitcoin Funds Swung From $528 Million In to $636 Million Out

U.S. spot bitcoin funds lost a net $635.6 million on Thursday, per Farside Investors, the largest outflow since June 25, according to SoSoValue. A day earlier they had taken in about $528 million. Bitcoin fell about 3%. Then it held near $81,700 overnight, on its 50-day average. That is close to the roughly $81,500 Glassnode estimates fund holders paid. October's flows turned negative, by SoSoValue's count.

One kind of money can wait. The other just showed it won't.

Outlier Signal

The selloff split money by how fast it can leave. Investors pulled $636 million from daily-liquid bitcoin funds in one session. Private capital moves slower: OpenAI's backers are still negotiating about 47% above March, and lenders sitting on record fundraising are reaching for smaller borrowers.

The common view is that private markets are calmer. They are slower. The first cracks show in terms before marks, through a lower price in talks and riskier borrowers, and holders of locked funds would feel any repricing later.

OpenAI's final price is the cleanest test. A close at or above $1.25 trillion would say private demand is still deep. Friday's fund flows show whether daily money keeps leaving.

PARTNER SPOTLIGHT

AI CEO Issues Code Red: Prepare for Meltdown

The CEO of this AI company (click here to get the name, 100% free) just issued a CODE RED in an internal memo…

Warning his employees that they’re dealing with a critical situation.

Another company executive even implied they might need a government bailout.

And now Jim Rickards is predicting this company is about to go bust, in a full-blown AI meltdown that could be 10 times bigger than Lehman Brothers.

Click here to see the details and learn how to prepare.

Thursday brought real evidence. Markets priced the part still open: next quarter, pending rulings and a private price still in talks. Moderna's presentation, Moody's review and Brazil's vote land before Monday, while OpenAI's round and the Iran ruling may not arrive until later. Each will show whether prices read the gap or ran ahead of it.

Tickers: MS MRNA MRK USA FIX NEM PMI LIED CNBC CODE RED

More articles from FinancialMarkets.com